Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-110 in Painful Osteoarthritis of the Knee
2011-002144-27Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Oct 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Hu-alphaD11 in knee osteoarthritis (OA) and osteoarthritis (OA) (3 arms), sponsored by Abbott Laboratories. Primary endpoints: Pain intensity change from baseline to final evaluation and Safety and tolerability of ABT-110. Started Oct 2011; status: terminated.
02
Drugs
Hu-alphaD11
03
Conditions
knee osteoarthritis (OA)osteoarthritis (OA)
Beyond the preview
Go deeper on 2011-002144-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002144-27.